Lung tumors hijack nerves to starve the body

A quiet but devastating syndrome

Cachexia affects roughly half of cancer patients and is believed to account for a quarter of all deaths linked to the disease, according to the Cleveland Clinic. This syndrome causes severe loss of muscle and fat, reduces quality of life, and sometimes even limits the treatment options available to patients.

A study published on July 2, 2026 in the journal Science, led by researcher Thales Papagiannakopoulos, at the time at the NYU Grossman School of Medicine and now an incoming professor at the Salk Institute, reveals an unsuspected mechanism behind this phenomenon: certain lung tumors communicate directly with the brain to trigger this muscle wasting, a finding that overturns decades of assumptions built almost entirely on general nutritional theories of cancer decline.

Why this discovery changes things

Until now, cachexia was mostly understood as a general metabolic consequence of cancer. This new research instead demonstrates a direct dialogue between certain tumors and the peripheral nervous system, opening the door to targeted treatments far more precise than the general nutritional approaches used until now, and forcing clinicians to reconsider how they explain sudden, unexplained weight loss to worried families.

An unprecedented signaling mechanism

According to the study published in Science, certain lung tumors use a lipid signaling molecule called prostaglandin E2, or PGE2, to communicate with sensory neurons located directly in the lung, which then relay this signal to the brain.

This specific subtype of lung cancer produces markedly higher levels of PGE2 than other tumor subtypes, which would explain why some patients develop severe cachexia while others, with comparably sized tumors, do not, a variability that has long puzzled oncologists trying to predict which patients will decline the fastest.

Verdict: confirmed by several converging experiments

Researchers showed that blocking half of the sensory connections between the lungs and the brain, or completely disabling the lung nerves involved, significantly reduced cachexia symptoms in animal models, confirming the causal role of this neural pathway.

The unexpected role of fat and omega-3s

The study shows that mice fed a diet high in fat developed more severe cachexia, while switching to a diet containing only omega-3 fatty acids limited the body's ability to produce PGE2, thereby preventing tumors from using this molecule to communicate with the nervous system.

When mice were genetically modified to no longer produce PGE2, cachexia simply did not develop, a result that confirms the central role of this specific molecule in the entire mechanism observed.

Verdict: confirmed, with concrete nutritional implications

Smaller-scale trials also showed that administering aspirin and ibuprofen, two common anti-inflammatory drugs that reduce prostaglandin production, also prevented the development of cachexia in the mice tested.

A scale underestimated by the general public

A German study from 2015, cited as a reference in the current work, already estimated that cachexia affected roughly nine million people worldwide, a figure that illustrates the scale of a syndrome that remains largely unknown to the general public compared to other cancer complications.

This scale is partly explained by the fact that cachexia is not limited to lung cancer: it accompanies many serious chronic diseases, although the neural mechanism discovered here appears particularly relevant to certain specific subtypes of lung tumors.

Verdict: confirmed, a global public health issue

The figure of a quarter of cancer deaths attributable to cachexia, put forward by the Cleveland Clinic, places this syndrome among the most significant causes of mortality in oncology, amply justifying the newly focused scientific attention on its precise mechanisms.

A therapeutic avenue still to be validated in humans

Researchers suggest this discovery could pave the way for new treatments specifically targeting the PGE2 signaling pathway or the sensory neurons involved, rather than being limited to the general nutritional approaches currently used to manage cachexia in cancer patients.

Lead researcher Thales Papagiannakopoulos says he wants to precisely identify which neurons and which brain circuits are involved, before exploring whether these same circuits also play a role in other symptoms frequently reported by cancer patients, such as depression or memory loss.

Verdict: promising but still at the preclinical stage

All of these findings currently come from animal models, and no human clinical trial has yet been conducted to validate the efficacy or safety of an intervention targeting this specific neural pathway in lung cancer patients.

A collaboration between several leading institutions

The study was conducted with the participation of researchers from the NYU Grossman School of Medicine, the Salk Institute, Harvard, Rutgers University, Princeton, Cold Spring Harbor, and several other leading American institutions, with financial support from the National Institutes of Health, underscoring how much coordinated public investment was required to trace a single molecular signal across so many disciplines.

This collaborative scale reflects the complexity of the subject studied, which combines expertise in oncology, neuroscience, and metabolism, three fields that rarely communicate this closely in traditional cancer research.

Verdict: a serious and transparent scientific effort

Publication in a journal as rigorously peer-reviewed as Science, with complete methodological data and clearly documented institutional funding, lends solid credibility to this study's conclusions, despite its still-preclinical limitations.

A lead toward depression and memory loss in patients

Beyond cachexia alone, researchers are now wondering whether the same neural circuits hijacked by lung tumors might also be involved in other symptoms frequently reported by cancer patients, notably depression and memory disorders.

Postdoctoral researcher Stefan Kotschi, a co-author of the study, notes that precisely identifying these neurons and their brain connections could open a much broader window into how a tumor affects the entire body, far beyond weight loss alone.

Verdict: a serious hypothesis, still to be confirmed

This potential extension of the discovery remains, at this stage, a hypothesis for future research rather than an established result, but it illustrates the scale of the possible consequences of a better understanding of the dialogue between tumors and the nervous system.

Limits that must absolutely be respected

This study does not demonstrate that all lung cancers cause cachexia through this same precise mechanism, nor that the results obtained in mice will automatically transfer, without adaptation, to human patients, an essential caution in preclinical research.

Nor does it allow us to claim that a simple dietary change, such as adopting an omega-3-rich diet, would by itself be enough to treat cachexia in patients already affected, without specialized and individualized medical guidance.

Necessary caution against media enthusiasm

It would be irresponsible to present this discovery as an immediately available treatment, when the researchers themselves stress the need for further research to precisely identify the exact neural circuits involved in humans.

This scientific honesty, far from diminishing the value of the discovery, is instead the best guarantee of long-term credibility for patients who hope to one day benefit from treatments derived from this work.

A new bridge between neuroscience and oncology

This discovery illustrates just how porous the boundary between neuroscience and oncology is becoming, opening research prospects that would have seemed improbable just a decade ago in treating the most aggressive lung cancers.

Measured hope for the future of patients

If the next stages of research confirm the possibility of therapeutically targeting this signaling pathway in humans, millions of patients worldwide could one day benefit from treatments capable of preserving their muscle mass during their fight against cancer, a real hope that still needs to be clinically confirmed in the years ahead.

By Maxime Marquette, columnist

Editorial stance

I am not a journalist but a columnist and analyst. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. I claim analytical clarity, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

Method and sources

This text keeps the basic distinction between verified facts and interpretive analysis. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under Sources, never here.

Primary source families used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

Secondary source families: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under Sources.

Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a critical, contextual synthesis based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.